News
ABVX
125.70
-4.16%
-5.46
Weekly Report: what happened at ABVX last week (0720-0724)?
Weekly Report · 1h ago
Abivax price target raised to $180 from $132 at Morgan Stanley
TipRanks · 2d ago
Sofinnova Crossover I cuts Abivax voting rights stake below 5% to 4.92%
PUBT · 3d ago
Abivax names new global heads of marketing, sales and market access in commercial leadership shake-up
PUBT · 3d ago
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis
Benzinga · 3d ago
Palisade Bio jumps following Oppenheimer outperform initiation
Seeking Alpha · 3d ago
Marshall Wace discloses net short position in Abivax
PUBT · 3d ago
PDT Partners discloses net short position in Abivax shares
PUBT · 5d ago
JPMorgan Chase raises Abivax stake above 5% to 5.36%
PUBT · 6d ago
PDT Partners discloses net short position in Abivax shares
PUBT · 6d ago
Weekly Report: what happened at ABVX last week (0713-0717)?
Weekly Report · 07/20 09:27
Abivax re-engages Centerview amid renewed takeover interest, La Lettre says
TipRanks · 07/17 18:10
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre
Benzinga · 07/17 18:04
Abivax reports 87,177,069 issued shares, 89,524,616 voting rights as of July 6, 2026
PUBT · 07/17 16:00
PDT Partners discloses net short position in Abivax shares
PUBT · 07/17 13:34
Abivax: Obefazimod Goes The Distance And So Does My Buy Rating
Seeking Alpha · 07/16 14:25
Valerio Therapeutics, Abivax team up on preclinical RNA therapeutics for immune-mediated inflammatory diseases
PUBT · 07/16 07:07
Valerio Therapeutics enters exclusive R&D collaboration with Abivax, secures up to €2.4 million upfront
PUBT · 07/16 06:11
Marshall Wace discloses net short position in Abivax
PUBT · 07/13 13:47
U.S. Chess Champion Backs Out Of Abivax and Casey’s, But Keeps Outpacing the S&P 500
TipRanks · 07/13 12:04
More
Webull provides a variety of real-time ABVX stock news. You can receive the latest news about Abivax S.A. through multiple platforms. This information may help you make smarter investment decisions.
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.